The aim of the study was to investigate the relationship between glucose effectiveness (Sg) and some metabolic parameters in male and female young Japanese.
Methods:
We measured plasma glucose and immunoreactive insulin levels in 1309 young Japanese persons (age <40 years) with normal glucose tolerance (NGT) before and at 30, 60, and 120 min during a 75 gram oral glucose tolerance test. We also measured serum adiponectin and high-sensitivity C-reactive protein (hsCRP) levels and oral glucose effectiveness (SgIO), and investigated factors related to SgIO.
Results:
The results of Spearman correlation analysis revealed that high-density lipoprotein cholesterol (HDL) and adiponectin were positively correlated with SgIO, whereas the proportion of males, body mass index, waist circumference (WC), systolic blood pressure (SBP), diastolic blood pressure, triglycerides (TG), and hsCRP were inversely correlated with SgIO. The results of multiple regression analysis indicated negative correlations between SgIO and the proportion of males, WC, and SBP and a positive correlation with HDL. The results of multiple regression analysis excluding WC indicated negative correlations between SgIO and the proportion of males, SBP, and TG and positive correlations with HDL and adiponectin.
Conclusions:
Sg decreased with a subtle worsening of metabolic parameters, even in young persons with NGT. Decreased Sg may be involved in the development of glucose intolerance in individuals with worse metabolic parameters.
Get full access to this article
View all access options for this article.
References
1.
BergmanRN, FinegoodDT, AderM. Assessment of insulin sensitivity in vivo. Endocr Rev, 1985; 6:45–86.
2.
NagasakaS, TokuyamaK, KusakaI, et al.Endogenous glucose production and glucose effectiveness in type 2 diabetic subjects derived from stable-labeled minimal model approach. Diabetes, 1999; 48:1054–1060.
3.
TaniguchiA, FukushimaM, SakaiM, et al.Insulin secretion, insulin sensitivity, and glucose effectiveness in nonobese individuals with varying degrees of glucose tolerance. Diabetes Care, 2000; 23:127–128.
4.
TokuyamaY, SakuraiK, YaguiK, et al.Pathophysiologic phenotypes of Japanese subjects with varying degrees of glucose tolerance: Using the combination of C-peptide secretion rate and minimal model analysis. Metabolism, 2001; 50:812–818.
5.
LorenzoC, WagenknechtLE, KarterAJ, et al.Cross-sectional and longitudinal changes of glucose effectiveness in relation to glucose tolerance: The insulin resistance atherosclerosis study. Diabetes Care, 2011; 34:1959–1964.
6.
DoiK, TaniguchiA, NakaiY, et al.Decreased glucose effectiveness but not insulin resistance in glucose-tolerant offspring of Japanese non-insulin-dependent diabetic patients: A minimal-model analysis. Metabolism, 1997; 46:880–883.
7.
KahnSE, PrigeonRL, McCullochDK, et al.The contribution of insulin-dependent and insulin-independent glucose uptake to intravenous glucose tolerance in healthy human subjects. Diabetes, 1994; 43:587–592.
8.
BestJD, KahnSE, AderM, et al.Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care, 1996; 19:1018–1030.
9.
TonelliJ, KishoreP, LeeDE, et al.The regulation of glucose effectiveness: How glucose modulates its own production. Curr Opin Clin Nutr Metab Care, 2005; 8:450–456.
10.
NagasakaS, KusakaI, YamashitaK, et al.Index of glucose effectiveness derived from oral glucose tolerance test. Acta Diabetol, 2012; 49(Suppl 1):S195–S204.
11.
WeissR, MaggeSN, SantoroN, et al.Glucose effectiveness in obese children: Relation to degree of obesity and dysglycemia. Diabetes Care, 2015; 38:689–695.
12.
SpreghiniN, CianfaraniS, SpreghiniMR, et al.Oral glucose effectiveness and metabolic risk in obese children and adolescents. Acta Diabetol, 2019; 56:955–962.
13.
ChenYL, LeeSF, PeiC, et al.Predicting glucose effectiveness in Chinese participants using routine measurements. Metab Syndr Relat Disord, 2016; 14:386–390.
14.
JiangY, OweiI, WanJ, EbeniboS, et al.Adiponectin levels predict prediabetes risk: The Pathobiology of Prediabetes in A Biracial Cohort (POP-ABC) study. BMJ Open Diabetes Res Care, 2016; 4:e000194.
15.
WangY, MengRW, KunutsorSK, et al.Plasma adiponectin levels and type 2 diabetes risk: A nested case-control study in a Chinese population and an updated meta-analysis. Sci Rep, 2018; 8:406.
16.
YatagaiT, NagasakaS, TaniguchiA, et al.Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism, 2003; 52:1274–1278.
17.
KimSM, ChoKH, ParkHS. Relationship between plasma adiponectin levels and the metabolic syndrome among Korean people. Endocr J, 2006; 53:247–254.
18.
TaniguchiA, NagasakaS, FukushimaM, et al.C-reactive protein and insulin resistance in non-obese Japanese type 2 diabetic patients. Metabolism, 2002; 51:1578–1581.
19.
den EngelsenC, KoekkoekPS, GorterKJ, van den DonkM, Salomé PL, Rutten GE. High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population: A cross-sectional analysis. Cardiovasc Diabetol, 2012; 11:25.
20.
SeinoY, NanjoK, TajimaN, et al.Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig, 2010; 1:212–228.
21.
MuraiN, SaitoN, KodamaE, et al.Association of ghrelin dynamics with beta cell function in Japanese subjects with normal glucose tolerance. Clin Endocrinol (Oxf), 2019; 91:616–623.
22.
MuraiN, SaitoN, KodamaE, et al.Insulin and proinsulin dynamics progressively deteriorate from within the normal range toward impaired glucose tolerance. J Endocr Soc, 2020; 4:bvaa066.
23.
MatsudaM, DeFronzoRA. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care, 1999; 22:1462–1470.
24.
SeltzerHS, AllenEW, HerronAL, et al.Insulin secretion in response to glycemic stimulus: Relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest, 1967; 46:323–335.
25.
PhillipsDI, ClarkPM, HalesCN, et al.Understanding oral glucose tolerance: Comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med, 1994; 11:286–292.
26.
MatsuzawaY. Metabolic syndrome—Definition and diagnostic criteria in Japan. J Atheroscler Thromb, 2005; 12:301.
27.
AlbertiKGMM, ZimmetP, ShawJ. Metabolic syndrome—A new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med, 2006; 23:469–480.
28.
PetersenKF, LaurentD, RothmanDL, et al.Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans. J Clin Invest, 1998; 101:1203–1209.
29.
AistonS, AndersenB, AgiusL. Glucose 6-phosphate regulates hepatic glycogenolysis through inactivation of phosphorylase. Diabetes, 2003; 52:1333–1339.
30.
SchwartzMW, SeeleyRJ, TschöpMH, et al.Cooperation between brain and islet in glucose homeostasis and diabetes. Nature, 2013; 503:59–66.
31.
RuudJ, SteculorumSM, BrüningJC. Neuronal control of peripheral insulin sensitivity and glucose metabolism. Nat Commun, 2017; 8:15259.
32.
CareyM, Lontchi-YimagouE, MitchellW, et al.Central K channels modulate glucose effectiveness in humans and rodents. Diabetes, 2020; 69:1140–1148.
33.
PartonLE, YeCP, CoppariR, et al.Glucose sensing by POMC neurons regulates glucose homeostasis and is impaired in obesity. Nature, 2007; 449:228–232.
34.
HawkinsM, TonelliJ, KishoreP, et al.Contribution of elevated free fatty acid levels to the lack of glucose effectiveness in type 2 diabetes. Diabetes, 2003; 52:2748–2758.
35.
TchernofA, DesprésJP. Pathophysiology of human visceral obesity: An update. Physiol Rev, 2013; 93:359–404.
36.
Cabezas-CerratoJ, Garcia-EstevezDA, AraújoD, et al.Insulin sensitivity, glucose effectiveness, and beta-cell function in obese males with essential hypertension: Investigation of the effects of treatment with a calcium channel blocker (diltiazem) or an angiotensin-converting enzyme inhibitor (quinapril). Metabolism, 1997; 46:173–178.
37.
BurattiniR, Di NardoF, BoemiM, et al.Deterioration of insulin sensitivity and glucose effectiveness with age and hypertension. Am J Hypertens, 2006; 19:98–102.
38.
StiefelP, MirandaML, Rodríguez-PurasMJ, et al.Glucose effectiveness is strongly related to left ventricular mass in subjects with stage I hypertension or high-normal blood pressure. Am J Hypertens, 2004; 17:146–153.
39.
CeddiaRB, SomwarR, MaidaA, et al.Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia, 2005; 48:132–139.
40.
YanaiH, YoshidaH. Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: Mechanisms and perspectives. Int J Mol Sci, 2019; 20:1190.
41.
MalmströmH, WalldiusG, CarlssonS, et al.Elevations of metabolic risk factors 20 years or more before diagnosis of type 2 diabetes: Experience from the AMORIS study. Diabetes Obes Metab, 2018; 20:1419–1426.
42.
ShahSS, RamirezCE, PowersAC, et al.Hyperglycemic clamp-derived disposition index is negatively associated with metabolic syndrome severity in obese subjects. Metabolism, 2016; 65:835–842.
43.
LinJD, HseihCH, LiuCC, et al.Estimation of the disposition index based on components of metabolic syndrome. Endocr J, 2014; 61:789–796.
44.
Garca-EstévezDA, Araújo-VilarD, Saavedra-GonzálezA, et al.Analysis of the relationship between body mass index, insulin resistance, and beta-cell function: A cross-sectional study using the minimal model. Metabolism, 2004; 53:1462–1466.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
